Role of direct‐acting antivirals in people with HIV ‐associated non‐Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi
British Journal of Haematology · 2026-11 · 209 (5) · 2083-2093
DOI: 10.1111/bjh.70793 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, online erschienen am 04.09.2026. Verfasst von Michele Merli und 34 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, HIV Infections, Lymphoma, Non-Hodgkin, Hepatitis C, Chronic. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Chronic hepatitis C virus (HCV) infection is common among patients with human immunodeficiency virus (HIV)‐related non‐Hodgkin lymphoma (NHL). Although direct‐acting antivirals (DAAs) achieve high sustained virological response (SVR) rates, data on their effects in people with HIV and HCV and affected by NHL remain limited. We conducted a retrospective study of 67 consecutive NHL patients with HIV and HCV (48 diffuse large B‐cell lymphoma [DLBCL]) treated at 14 Italian centres (2010–2024). All patients received concomitant anti‐retroviral therapy (ART). The median age was 51 years. The majority of patients were male (91%) and people who inject drugs (70%). Most patients (94%) received curative first‐line immunochemotherapy (I‐CT), mainly rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP). After 2016, 26 patients received DAAs (8 concurrently, 18 after I‐CT). DAA toxicity was minimal, and SVR was achieved in all cases. With a median follow‐up of 91 months, the 3‐year overall survival (OS) was 61%. Patients treated with DAAs had better 5‐year OS (81% vs. 48%, p = 0.035), with no difference between those who received DAAs subsequently or concurrently with I‐CT. Multivariate analysis identified high age‐adjusted International Prognostic Index (aaIPI), HIV score 3–6, female sex and absence of rituximab treatment as independent risk factors for OS, while DAAs had a borderline impact ( p = 0.055). In conclusion, DAA therapy during or after I‐CT is feasible, safe and highly effective in this high‐risk group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
- Hematology, University Hospital "Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi", University of Insubria, Varese, Italy.
- National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome, Italy.
- Department of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy.
- Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
- Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
ORCID-Profile: Michele Merli, Benedetta Bianchi, Michele Bibas, Davide Dalu, Emanuele Ravano, Giovanni Rindone, Guido Gini, Carlo Visco, Emanuele Cencini, Dario Marino, Massimo Gentile, Valentina Zuccaro, Cristina Rovelli, Valentina Mazzotta, Vittorio Ruggero Zilioli, Carmela Pinnetti, Nicla La Verde, Paolo Grossi, Luigi Marcheselli, Marta Coscia, Francesco Passamonti, Michele Spina, Luca Arcaini, Alessandro Re
Zitieren
APA
Merli, M., Bianchi, B., Bibas, M., Dalu, D., Daffini, R., Ravano, E., Rindone, G., Gini, G., Visco, C., Tisi, M. C., Cencini, E., Marino, D., Gentile, M., Zuccaro, V., Rovelli, C., Mazzotta, V., Fasola, C., Zilioli, V. R., Verga, L., …, & Re, A. (2026). Role of direct‐acting antivirals in people with HIV ‐associated non‐Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi. British Journal of Haematology, 209(5), 2083-2093. https://doi.org/10.1111/bjh.70793
Vancouver
Merli M, Bianchi B, Bibas M, Dalu D, Daffini R, Ravano E, et al. Role of direct‐acting antivirals in people with HIV ‐associated non‐Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi. British Journal of Haematology. 2026;209(5):2083-2093. doi:10.1111/bjh.70793
BibTeX
@article{Merli2026,
author = {Merli, Michele and Bianchi, Benedetta and Bibas, Michele and Dalu, Davide and Daffini, Rosa and Ravano, Emanuele and Rindone, Giovanni and Gini, Guido and Visco, Carlo and Tisi, Maria Chiara and Cencini, Emanuele and Marino, Dario and Gentile, Massimo and Zuccaro, Valentina and Rovelli, Cristina and Mazzotta, Valentina and Fasola, Cinzia and Zilioli, Vittorio Ruggero and Verga, Luisa and Pinnetti, Carmela and Gotti, Manuel and Rossi, Francesca Gaia and Rampi, Nicolò and Ferrario, Andrea and Pagani, Chiara and Pagnucco, Layla and Verde, Nicla La and Grossi, Paolo and Bandera, Alessandra and Marcheselli, Luigi and Coscia, Marta and Passamonti, Francesco and Spina, Michele and Arcaini, Luca and Re, Alessandro},
title = {Role of direct‐acting antivirals in people with HIV ‐associated non‐Hodgkin lymphoma and concomitant HCV infection: A study on behalf of the Fondazione Italiana Linfomi},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {5},
pages = {2083--2093},
doi = {10.1111/bjh.70793}
}
EUVIMED